Evidence map›Paper›PMID 42177456›Full record

ArticleBMC biotechnology2026

Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer.

Jianhua Wen, Liangyi Wei, Jun Huang, Liujuan Zhou, Jiayin Yu, Hualin Cao, Haiqi Liang, Min Qin, Zelin Cui, Hao Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jianhua Wen *Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Liangyi Wei *Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Jun HuangState Key Laboratory of Non-Food Biomass Energy Technology, Institute of Biological Sciences and Technology, Guangxi Academy of Sciences, Nanning, Guangxi, 530007, China.
Liujuan ZhouAssembly Medicine, LLC, Shanghai, 201203, China.
Jiayin YuDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Hualin CaoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Haiqi LiangDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Min QinDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Zelin CuiDepartment of Urology, The Central Hospital of Yongzhou/Yongzhou Hospital Affiliated to University of South China, Yongzhou, Hunan, 425000, China.
Hao ChenDepartment of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, 410005, China.
Yujian LiDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Jiawen ZhaoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China.
Fubo WangCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, China. wangfubo@gxmu.edu.cn.
Siming LiaoState Key Laboratory of Non-Food Biomass Energy Technology, Institute of Biological Sciences and Technology, Guangxi Academy of Sciences, Nanning, Guangxi, 530007, China. simingliao@gxas.cn.
Jiwen ChengDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530000, China. chengjiwen@stu.gxmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced bladder cancer (BCa) is associated with a poor prognosis, highlighting the urgent need for novel therapeutic strategies with improved efficacy and reduced toxicity. Nectin-4 (PVRL4, here after referred to as N4) is a clinically validated therapeutic target; however, existing antibody-based agents are limited by inadequate tumor penetration and off-target toxicities. Nanobodies (Nbs) possess favorable characteristics, including small molecular size, enhanced tissue penetration, and ease of sengineering. This study aimed to identify and preliminarily characterize N4-targeting Nb candidates for BCa using a yeast surface display-based screening strategy.

resultsN4 was highly expressed in BCa and significantly associated with an unfavorable prognosis. The YSD platform supported efficient library expansion, surface display, and iterative enrichment of N4-binding clones. Among the identified Nbs, Nb-80 exhibited apparent binding activity, with an EC₅₀ of 0.150 μg/mL. BLI analysis demonstrated rapid association-dissociation kinetics.

conclusionsAn N4-binding Nb candidate was identified and preliminarily characterized using a YSD-based screening strategy. These findings support the utility of the YSD platform for Nb discovery and provide a preliminary basis for further validation of N4-targeting Nb candidates in BCa. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Cell Adhesion MoleculesCell Surface Display TechniquesNectinsSaccharomyces cerevisiaeSingle-Domain AntibodiesUrinary Bladder NeoplasmsHumansCell Adhesion MoleculesNECTIN4 protein, humanNectinsSingle-Domain AntibodiesBioinformaticsBladder cancerNanobodyNectin-4Yeast surface display

Identifiers

PMID42177456
PMCPMC13587289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.